Urine drug monitoring, often known as UDM, is an essential instrument for screening patients who are receiving opioid medication for adherence and identifying potential instances of misuse and abuse. The necessity of UDM as a standard of care is emphasized several times across the various guidelines for opioid therapy. It is suggested that all patients who are receiving long-term opioid therapy undergo routine and random monitoring prior to the beginning of treatment and even while they are receiving treatment. The recommended frequency of UDM varies from person to person and is determined by clinical judgment and individual risk assessment. As is the case with any other diagnostic or monitoring test, the objective of UDM should be to direct treatment and enhance the quality of care provided to patients. Inappropriate interpretation of the results and inability to arrange definitive testing when it is necessary can have a negative impact on patient care. It is essential for pharmacists to be able to determine the right dosage and excretion of various medications in this section together.